A phase I/IIa clinical trial in Duchenne muscular dystrophy using systemically delivered morpholino antisense oligomer to skip exon 53

Project Information

SKIP-NMD

Grant agreement ID: 305370

Project closed

Start date 1 November 2012

End date 30 April 2016

Funded under

• Specific Programme "Cooperation": Health

Total cost € 7 527 838,99

EU contribution € 5 512 424,07

Coordinated by

UNIVERSITY COLLEGE LONDON

• New treatment to slow muscle wastage in boys with DMD
  EN